Trending: Sanofi's Notus Trial Meets Primary Endpoint
27 Novembre 2023 - 4:31PM
Dow Jones News
10:01 ET -- Sanofi is one of the most mentioned companies in the
U.S. across all news items in the last 12 hours, according to
Factiva data. Sanofi said a second phase 3 trial of Dupixent met
its primary endpoint with what the company said was overwhelming
efficacy. Sanofi said its Notus trial confirmed positive published
results from the Phase 3 Boreas trial. The Notus trial found that
the treatment "significantly reduced exacerbations," and that
treatment with Dupixent led to rapid and significant improvements
in lung function for patients with the life-threatening respiratory
disease COPD. Dow Jones & Co. owns Factiva.
(chris.wack@wsj.com)
(END) Dow Jones Newswires
November 27, 2023 10:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Sanofi (NASDAQ:SNY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024